Minerva Neurosciences (NERV), a clinical-stage biopharma focused on CNS diseases, reported for the nine months ended September 30, 2025, operating at a substantial loss, necessitating recent significant financing. The company remains pre-revenue and dependent on external capital.
Financial & Liquidity Status: The company experienced a severe profitability reversal: 9M 2024 income of \(5.71M swung to a **\)9.76M Net Loss** in 9M 2025. This shift is primarily due to the absence of a significant $26.6M non-recurring “Other Income” event recorded in the prior year related to the Seltorexant roy
...